ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

IXI Ixico Plc

8.75
0.00 (0.00%)
24 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Ixico Plc LSE:IXI London Ordinary Share GB00BFXR4C20 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 8.75 8.50 9.00 8.75 8.75 8.75 366 07:38:41
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

IXICO plc Annual Report and Accounts and Notice of AGM (2739U)

16/01/2017 2:00pm

UK Regulatory


Ixico (LSE:IXI)
Historical Stock Chart


From Apr 2019 to Apr 2024

Click Here for more Ixico Charts.

TIDMIXI

RNS Number : 2739U

IXICO plc

16 January 2017

16 January 2017

FOR IMMEDIATE RELEASE

IXICO plc

("IXICO" or the "Company")

Annual Report and Accounts and Notice of AGM

IXICO PLC (Ticker: IXI), the brain health company, announces that its Annual Report and Accounts for the year ended 30 September 2016 and its Notice of Annual General Meeting (AGM) have been distributed to shareholders.

The AGM will be held at 9.30 am on Monday 30 January 2017 at the offices of FTI Consulting LLP, 200 Aldersgate Street, London, EC1A 4HD.

The Company's Annual Report and Accounts, which incorporates the Notice of AGM, are available on the Company's website http://ixico.com/investors/rns-announcements.

For further information please contact:

 
 IXICO plc 
  Derek Hill, Chief Executive Officer        Tel: +44 20 
  Susan Lowther, Chief Financial Officer     3763 7499 
 
 Shore Capital (Nomad and Broker)          Tel: +44 20 
  Bidhi Bhoma / Edward Mansfield            7408 4090 
 
 FTI Consulting Limited (Investor          Tel: +44 20 
  Relations)                                3727 1000 
  Simon Conway/Mo Noonan/Matthew Moss 
 

About IXICO

IXICO's innovative and proprietary digital healthcare technologies help those involved in researching and treating serious diseases to capture and analyse clinical data to make rapid, informed decisions. In clinical research this includes the phenotyping of patients, quantification of disease pathology and measurement of patient outcomes. In clinical practice the mobile health and digital decision support technologies aid diagnosis, patient engagement and monitoring. IXICO is also collaborating with partners to develop companion digital health products targeted at improving patient outcomes.

The Company's brain health focus includes Alzheimer's disease, Huntington's disease, multiple sclerosis, Parkinson's disease, behavioural health, child and adolescent mental health.

More information is available on www.ixico.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCSFLFDMFWSEIF

(END) Dow Jones Newswires

January 16, 2017 09:00 ET (14:00 GMT)

1 Year Ixico Chart

1 Year Ixico Chart

1 Month Ixico Chart

1 Month Ixico Chart

Your Recent History

Delayed Upgrade Clock